SS31 10MG

SS31 is a peptide derived from the human protein cardiokine, known for its potential protective effects on mitochondrial function and cellular integrity. This product is provided for academic and research purposes only within approved institutional settings. Below is a detailed overview of its biochemical characteristics and research applications.

Research Context

SS31, also referred to as a mitochondrial protective peptide, has gained attention in the scientific community for its ability to attenuate mitochondrial dysfunction associated with aging, metabolic disorders, and oxidative stress. Originally isolated from the human protein serine serine-rich nuclear protein 31 (SS31), it has shown promise in preclinical studies investigating its role in preserving cellular energy homeostasis.

Research Overview

SS31 operates primarily through mechanisms involving the stabilization of mitochondrial membranes, reduction of lipid peroxidation, and enhancement of cellular resilience against stressors such as ischemia-reperfusion injury, diabetes, and neurodegenerative conditions. Its biochemical properties include:

• Potential anti-apoptotic effects through mitochondrial membrane protection.
• Neutralization of reactive lipid species that compromise mitochondrial integrity.
• Support for metabolic regulation in models of insulin resistance.

Key Research Focus Areas

Biochemical Mechanisms:

• Mitochondrial Protection: SS31 is believed to inhibit the formation of lipid peroxides that disrupt mitochondrial membranes, thereby preserving energy production and cellular viability.
• Antioxidant Activity: Preclinical studies suggest its ability to mitigate oxidative damage through modulation of lipid peroxidation cascades.

Physiological Applications:

• Metabolic Health: Emerging research explores SS31’s potential in improving glucose tolerance and insulin sensitivity in preclinical models.
• Neurodegeneration: Investigations into its effects on mitochondrial dysfunction in models of Alzheimer’s disease and Parkinson’s disease are ongoing.
• Cardiovascular Disease: Animal studies have examined its role in reducing myocardial injury post-ischemia and reperfusion.

Safety and Compliance

Due to its structural and functional similarities to natural peptides, SS31 exhibits low immunogenicity in preclinical assessments. However, rigorous safety evaluations are essential in research settings, particularly when administered in systemic or sustained-release formats. Always adhere to institutional protocols for peptide handling and storage, as improper conditions may compromise experimental integrity. This product is intended for use in approved academic or industrial research facilities only.

For research use only. Not for human or animal consumption.